Literature DB >> 5286990

Studies on the absorption, distribution, and excretion of hydroxyurea (NSC-32065).

F Rosner, H Rubin, F Parise.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5286990

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  5 in total

1.  Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.

Authors:  K S Albain; L J Swinnen; L C Erickson; P J Stiff; R I Fisher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

Authors:  David Dingli; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

3.  A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.

Authors:  J J Beitler; R V Smith; H Haynes; C E Silver; A Quish; T Kotz; M Serrano; A Brook; S Wadler
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

4.  [Partial synchronization of tumor cells in vivo with hydroxyurea (author's transl)].

Authors:  R Hartenstein; K Pfundmair; K Possinger
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977

5.  A phase I trial of high-dose continuous-infusion hydroxyurea.

Authors:  D C Smith; W P Vaughan; P R Gwilt; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.